.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The role of non-coding RNAs in muscular dystrophies has gained significant attention in recent years. Muscular dystrophies (MDs) involve progressive muscle wasting and weakness due to specific genetic mutations. However, beyond simple protein-coding defects, researchers now identify non-coding RNAs (ncRNAs) as critical mediators of the disease. In particular, microRNAs (miRNAs) act as post-transcriptional regulators that fine-tune physiological processes in healthy muscle tissue. When these pathways become dysregulated, they contribute to the initiation and maintenance of various MD subtypes.
Current research highlights four main pathomechanism themes involving these molecules. These include myogenesis insufficiency, structural instability, signaling failure, and destructive pathways. For instance, specific muscle-enriched miRNAs, known as \"myomiRs\" (such as miR-1, miR-133, and miR-206), show significant dysregulation in Duchenne muscular dystrophy. These molecules often leak into the bloodstream as muscle fibers degrade. Consequently, they serve as potentially valuable non-invasive biomarkers for monitoring disease progression and therapeutic response. Furthermore, other ncRNAs like long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) interact with miRNAs to influence muscle regeneration and fibrosis.
Clinicians must recognize that these epigenetic regulators offer a new layer of complexity in neuromuscular diseases. Understanding the interaction between miRNAs and their protein targets helps in developing targeted therapies. For example, some experimental treatments aim to \"sponge\" up overexpressed miRNAs or replace downregulated ones to restore muscle function. As the field evolves, these molecular signatures may eventually lead to personalized diagnostic tools for Indian patients with rare muscular disorders.
Yes, circulating miRNAs like miR-1 and miR-206 are being studied as minimally invasive biomarkers for disease severity and monitoring treatment efficacy in patients with muscular dystrophy.
They regulate key transcription factors and signaling pathways that control the proliferation and differentiation of myogenic progenitor cells, often acting as a bridge between genetic mutations and phenotypic expression.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.
References
Abdelrehim FG et al. Emerging roles of microRNAs and other non-coding transcriptome in muscular dystrophies. Inflamm Regen. 2026 Apr 11. doi: 10.1186/s41232-026-00415-7. PMID: 41964102.
Cazzella V, et al. Noncoding RNAs in Duchenne and Becker muscular dystrophies: role in pathogenesis and future prognostic and therapeutic perspectives. Front Genet. 2020;11:423. doi: 10.3389/fgene.2020.00423.
Eisenberg I, et al. Distinctive patterns of microRNA expression in primary muscular dystrophies. Proc Natl Acad Sci U S A. 2007;104(43):17016-17021.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A look into how microRNAs and other non-coding RNAs regulate pathomechanisms and serve as biomarkers in various muscular dystrophy subtypes....
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
